Oral antitumor for the treatment of mast cell tumors in dogs.
This product is no longer in stock
The mast cell tumor is the most common malignant skin tumor in dogs, accounting for between 16-21% of skin tumors. Their behavior and progression is quite heterogeneous ranging from distinct slow-growing tumors with low potential for metastasis to very aggressive undifferentiated tumors with plenty of metastasis.
The Masitinib, Masivet® active principle, is an inhibitor of tyrosine kinase and potently inhibits c-kit receptor selectivael.
Presentation: 50 and 150 mg. Packs of 30 tablets
No customer reviews for the moment.